{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:04:28Z","timestamp":1782205468400,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/igc.0b013e3182a809e0","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T09:11:44Z","timestamp":1383124304000},"page":"1577-1582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Stacey M.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tiersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"H\u00f6chster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie V.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achuta Kumar","family":"Guddati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182a809e0_bb0005","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0010","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0015","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.23425","article-title":"Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0020","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0025","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0030","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute\u2019s Anticancer Drug Screen panel","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem Pharmacol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0035","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0040","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.1999.17.8.2553","article-title":"Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group","volume":"17","author":"Hochster","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0045","first-page":"1245","article-title":"Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study","volume":"3","author":"Hochster","year":"1997","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2005.08.059","article-title":"New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology. Prolonged topotecan infusion with cisplatin in the firstline treatment of ovarian cancer: an NYGOG and ECOG study","volume":"100","author":"Hochster","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0055","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0060","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2007.11.017","article-title":"Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer","volume":"108","author":"Hochster","year":"2008","journal-title":"A phase I study. Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0070","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0075","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clinical Trials."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0085","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0090","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/annonc\/mdf030","article-title":"Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer","volume":"13","author":"Tortora","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0095","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0100","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/IGC.0b013e3181e4a6c1","article-title":"Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer","volume":"20","author":"Murgia","year":"2010","journal-title":"IntJ Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bjc.6604878","article-title":"Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group","volume":"100","author":"Ray-Coquard","year":"2009","journal-title":"BrJ Cancer."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0115","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0120","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"BrJ Cancer."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182a809e0_bb0135","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Eric Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24085529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24085529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182a809e0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:36:06Z","timestamp":1753101366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24085529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1048891X24085529"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182a809e0","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182a809e0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}